Parameter
| Biomarker | MGMT Promoter Meth | Full name | DNA Methylation (MGMT Promoter) | Molecular Type | DNA Methylation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, Prognosis |
| Disease | Meningioma | Disease Subtypes | / | ||
| Organ | Brain, Meninges | Test Sample / Technology Platform | Tumor Tissue (MSP, Pyrosequencing) | ||
| Pathobiological Mechanisms | Methylation silences the MGMT gene, enhances temozolomide chemotherapy sensitivity. | ||||
| Clinical Availability Status | Research Validation Stage | ||||
| Notes and Dynamics | The chemotherapy response rate is improved in methylation-positive patients, which can guide individualized treatment. | ||||